Where and when:
The talk will take place HT W3 Thursday February 2 at 6:30pm in Levine LT, Trinity College

After the talk, you will have the chance to talk with Prof Kouzarides in the Cats MCR.

A follow-up email reminder with further information will be sent out closer to the event.

About: 
Prof Tony Kouzarides has many titles: PhD FRS FMedSci Professor of Cancer Biology, Cancer Research UK Gibb Fellow, Director of the Milner Therapeutics Institute, and Member of Cambridge University Department of Pathology.

His lab has been studying epigenetic modifications for many years, starting with the identification of the first human enzymes to modify chromatin in 1996. His lab has identified and characterised many chromatin modification pathways and showed their involvement in cancer. The lab is now investigating the functions of mRNA modifications and their connections to cancer. In close collaboration with STORM Therapeutics, the Kouzarides lab is targeting RNA modification pathways with small molecule inhibitors, to develop drugs against cancer.

In the 22-year period of 1996-2017, Tony was listed in the top ten most-cited scientists at the University of Cambridge (in any field), as shown in the curated publication database of 100,000 top scientists world-wide.

Tony is also a co-founder and director of the Milner Therapeutics Institute, whose mission is to deliver better therapies through collaborations with industry. He is founder and director of Cambridge Gravity, an organisation for the promotion of science at the University of Cambridge. He is founder and patron of a cancer charity in Spain called Conquer Cancer (Vencer el Cancer). He is on the Scientific Advisory Board of the Institute of Cancer Research (UK) and on the Executive Board of the Cambridge Cancer Centre.

Tony is a co-founder and ex-director of Abcam plc, a publicly trading research reagents company in Cambridge, a co-founder and ex-director of Chroma Therapeutics, a drug discovery company based in Oxford, and a co-founder and current director of STORM Therapeutics, a drug discovery company based in Cambridge.